PRESS RELEASE published on 05/17/2024 at 22:30, 6 months 3 days ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance. The ADS Ratio Change will be effective on June 3rd, 2024, impacting ADS trading price. No impact on underlying ordinary shares Ordinary Shares Nasdaq Compliance DBV Technologies ADS Ratio Change Trading Price
BRIEF published on 05/16/2024 at 22:35, 6 months 4 days ago DBV Technologies announces the results of the 2024 Combined General Meeting General Assembly 2024 DBV Technologies Resolutions Adopted Allergy Treatment Biopharmaceutical Sector
PRESS RELEASE published on 05/16/2024 at 22:30, 6 months 4 days ago DBV Technologies Announces Results of its 2024 Combined General Meeting DBV Technologies announces successful results of its 2024 Combined General Meeting where shareholders approved all proposed resolutions. The Company focuses on treatment options for food allergies Resolutions Combined General Meeting DBV Technologies Food Allergies Treatment Options
BRIEF published on 05/09/2024 at 22:35, 6 months 11 days ago DBV Technologies announces its participation in two investor conferences in May DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
PRESS RELEASE published on 05/09/2024 at 22:30, 6 months 11 days ago DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
BRIEF published on 05/07/2024 at 22:35, 6 months 13 days ago DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE published on 05/07/2024 at 22:30, 6 months 13 days ago DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer
Published on 11/21/2024 at 14:00, 19 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 19 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 19 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 49 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 44 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 2 hours 4 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 21 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 59 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 34 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 34 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
